News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Biothera Acquires MUC1 Anti-Cancer Monoclonal Antibody From Antisoma PLC
March 10, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EAGAN, Minn.--(BUSINESS WIRE)--Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Antibody-drug conjugate (ADC)
Roche Inks Another China ADC Pact With $1.5B Hansoh Bet
October 17, 2025
·
2 min read
·
Tristan Manalac
Autoimmune disease
Sanofi Joins With EVOQ in $500M Autoimmune Alliance
October 16, 2025
·
2 min read
·
Tristan Manalac
Rare diseases
Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work
October 15, 2025
·
2 min read
·
Dan Samorodnitsky
ALS
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line
October 15, 2025
·
1 min read
·
Tristan Manalac
